Alexion Pharmaceuticals (ALXN) Holder Bank Of The West Lowered Its Position as Stock Declined; Nxp Semiconductors Nv (NXPI) Stock Value Declined While Private Asset Management Increased Position by $2.37 Million

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Logo

Bank Of The West decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 20.99% based on its latest 2018Q3 regulatory filing with the SEC. Bank Of The West sold 7,984 shares as the company’s stock declined 2.68% with the market. The institutional investor held 30,061 shares of the health care company at the end of 2018Q3, valued at $4.18 million, down from 38,045 at the end of the previous reported quarter. Bank Of The West who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $24.26 billion market cap company. The stock decreased 2.15% or $2.39 during the last trading session, reaching $108.74. About 986,211 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 7.37% since January 14, 2018 and is uptrending. It has outperformed by 7.37% the S&P500. Some Historical ALXN News: 20/04/2018 – $ALXN — Here is the official statement from Attorney General of the Union of Brazil “Soliris case was only the first to be tried by the STJ. Several other drugs in the same situation”; 11/04/2018 – ALEXION PHARMACEUTICALS INC ALXN.O SAYS TOTAL EQUITY VALUE OF TRANSACTION AMOUNTS TO SEK 7,100 MLN, OR APPROXIMATELY $855 MLN; 26/04/2018 – ALEXION PHARMACEUTICALS INC – PHASE 3 SWITCH STUDY ALSO DEMONSTRATED NON-INFERIORITY ON ALL FOUR KEY SECONDARY ENDPOINTS; 25/05/2018 – ALEXION PHARMACEUTICALS INC ALXN.O – OFFER FOR WILSON THERAPEUTICS MADE THROUGH A WHOLLY OWNED SUBSIDIARY OF CO; 15/03/2018 – Alexion Pharmaceuticals ALXN1210 Achieved Non-Inferiority to Soliris on Co-Primary Endpoints of Transfusion Avoidance and Lactate Dehydrogenase Normalization; 20/04/2018 – Alexion: Brazil Patent Issue Has No Implications for Intellectual Property Outside Brazil; 11/04/2018 – Alexion: Tender Offer Is Expected to Complete and the Transaction Is Expected to Close in the Second Quarter of 2018

Private Asset Management Inc increased its stake in Nxp Semiconductors Nv (NXPI) by 820% based on its latest 2018Q3 regulatory filing with the SEC. Private Asset Management Inc bought 27,880 shares as the company’s stock declined 18.87% with the market. The institutional investor held 31,280 shares of the semiconductors company at the end of 2018Q3, valued at $2.67 million, up from 3,400 at the end of the previous reported quarter. Private Asset Management Inc who had been investing in Nxp Semiconductors Nv for a number of months, seems to be bullish on the $23.35 billion market cap company. The stock decreased 0.58% or $0.46 during the last trading session, reaching $79.02. About 1.35 million shares traded. NXP Semiconductors N.V. (NASDAQ:NXPI) has declined 33.99% since January 14, 2018 and is downtrending. It has underperformed by 33.99% the S&P500. Some Historical NXPI News: 13/04/2018 – QCOM: China’s delay could imperil Qualcomm deal for NXP Semicond; 21/05/2018 – QUALCOMM INC – FOUR SERIES OF OUTSTANDING NOTES ARE INTENDED TO FINANCE ACQUISITION; 15/05/2018 – The Edge Markets: Qualcomm-NXP deal still on hold in China, trade talks with US eyed – sources – The Edge Markets; 19/04/2018 – Sources tell CNBC Qualcomm is “very concerned” with the fate of an NXP Semiconductors deal; 20/03/2018 – MOFCOM REVIEW OF NXPI/QUALCOMM REMAINS ON TRACK: REORG RESEARCH; 13/04/2018 – China Stalls Review of Qualcomm, Toshiba Deals; 19/04/2018 – QUALCOMM – CO’S UNIT AGREED IF REQUIRED REGULATORY APPROVALS NOT RECEIVED BY JULY 25, IT WILL PAY TERMINATION FEE TO NXP NO LATER THAN JULY 26, 2018; 02/05/2018 – NXP Semiconductors 1Q Rev $2.269B; 20/04/2018 – NXP SEMI GAINS PRE-MKT AS MSCC/MCHP UNDER MOFCOM SIMPLE REVIEW; 19/04/2018 – Qualcomm and NXP Agree, at MOFCOM Request, to Withdraw and Refile Application for Chinese Regulatory Approval

Investors sentiment decreased to 1.04 in 2018 Q3. Its down 0.16, from 1.2 in 2018Q2. It worsened, as 51 investors sold ALXN shares while 168 reduced holdings. 66 funds opened positions while 161 raised stakes. 203.25 million shares or 0.19% less from 203.64 million shares in 2018Q2 were reported. Essex Fincl Services Inc holds 1,872 shares. 4,900 were accumulated by Conning. Wellington Gp Llp holds 0% or 13,118 shares. Blackrock owns 0.1% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 16.30M shares. Bender Robert And Associate reported 32,613 shares or 2.06% of all its holdings. Globeflex Cap Ltd Partnership invested in 2,900 shares. 600 are held by Paradigm Asset Company Limited Liability. Raymond James Tru Na holds 0.02% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 2,683 shares. Tealwood Asset Mgmt reported 12,220 shares. Fjarde Ap stated it has 0.12% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Eqis Capital accumulated 0.15% or 20,030 shares. Mitsubishi Ufj Tru And Banking Corp accumulated 0.08% or 171,533 shares. Moreover, Gam Holdings Ag has 0.18% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 36,202 shares. Advisory Network Limited Co reported 0.01% stake. Atria Invests Ltd Liability Co owns 2,854 shares.

Since November 28, 2018, it had 0 insider purchases, and 2 selling transactions for $618,666 activity. HANTSON LUDWIG sold $310,937 worth of stock or 3,244 shares.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “Alexion Pharmaceuticals (ALXN) Shares Cross Above 200 DMA – Nasdaq” on March 09, 2018, also Seekingalpha.com with their article: “Alexion Pharmaceuticals beats by $0.28, beats on revenue – Seeking Alpha” published on October 24, 2018, Nasdaq.com published: “Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion – Nasdaq” on September 27, 2018. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Nasdaq.com and their article: “Alexion’s (ALXN) Earnings Beat Estimates in Q2, Guidance Up – Nasdaq” published on July 26, 2018 as well as Seekingalpha.com‘s news article titled: “Alexion’s Soliris shows treatment effect in late-stage rare CNS disorder; shares up 5% premarket – Seeking Alpha” with publication date: September 24, 2018.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 118 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Strong Buy” rating on Tuesday, September 1 by Raymond James. The firm earned “Buy” rating on Friday, October 27 by Stifel Nicolaus. The stock has “Outperform” rating by Leerink Swann on Monday, September 26. The stock has “Buy” rating by UBS on Thursday, February 4. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, June 13. Piper Jaffray maintained it with “Buy” rating and $17000 target in Tuesday, May 8 report. As per Tuesday, August 7, the company rating was downgraded by Stifel Nicolaus. The rating was upgraded by Vetr on Wednesday, August 12 to “Buy”. Credit Suisse maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, March 16 with “Outperform” rating. The rating was initiated by Oppenheimer with “Perform” on Thursday, December 15.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 14. They expect $1.61 earnings per share, up 25.78% or $0.33 from last year’s $1.28 per share. ALXN’s profit will be $359.19 million for 16.89 P/E if the $1.61 EPS becomes a reality. After $1.86 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -13.44% negative EPS growth.

Bank Of The West, which manages about $854.41M US Long portfolio, upped its stake in Home Depot Inc (NYSE:HD) by 5,619 shares to 54,030 shares, valued at $11.19 million in 2018Q3, according to the filing. It also increased its holding in Visa Inc (NYSE:V) by 3,729 shares in the quarter, for a total of 83,614 shares, and has risen its stake in Morgan Stanley (NYSE:MS).

More notable recent NXP Semiconductors N.V. (NASDAQ:NXPI) news were published by: Nasdaq.com which released: “Should Value Investors Buy NXP Semiconductors (NXPI) Stock? – Nasdaq” on August 03, 2018, also Seekingalpha.com with their article: “5 Reasons NXP Semiconductors Really Bottomed This Time – Seeking Alpha” published on November 04, 2018, Seekingalpha.com published: “NXP Semiconductors: Time To Buy The Dip? – Seeking Alpha” on July 11, 2018. More interesting news about NXP Semiconductors N.V. (NASDAQ:NXPI) were released by: Investorplace.com and their article: “5G Will Soon End the Winter of Discontent for Qualcomm Stock – Investorplace.com” published on December 26, 2018 as well as Investorplace.com‘s news article titled: “Why Qualcomm Stock Should Be a Mainstay In Any 5G Portfolio – Investorplace.com” with publication date: December 27, 2018.

Among 32 analysts covering NXP Semiconductors NV (NASDAQ:NXPI), 18 have Buy rating, 2 Sell and 12 Hold. Therefore 56% are positive. NXP Semiconductors NV had 93 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) has “Hold” rating given on Monday, June 11 by SunTrust. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) earned “Hold” rating by Suntrust Robinson on Friday, October 28. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) has “Buy” rating given on Wednesday, September 9 by Sterne Agee CRT. The firm has “Hold” rating by SunTrust given on Wednesday, October 11. The company was downgraded on Wednesday, September 12 by Stifel Nicolaus. Bernstein downgraded the shares of NXPI in report on Thursday, October 26 to “Market Perform” rating. The rating was maintained by Stifel Nicolaus on Friday, November 3 with “Hold”. Deutsche Bank downgraded the stock to “Hold” rating in Monday, June 19 report. The firm has “Hold” rating by Mizuho given on Wednesday, May 31. The firm has “Hold” rating by Jefferies given on Wednesday, October 18.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.